Results 41 to 50 of about 6,419 (213)
Frontiers in Pharmacology, 2022 Background: Our previous studies have shown that Yindan Jiedu granules (YDJDG) can effectively treat coronavirus disease 2019 (COVID-19); however, the high infectivity and the immune escape potential of the Omicron variant BA.2 make it more difficult to ...
Ying Feng +9 more
doaj +1 more source
Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
Therapies, 2023 Nirmatrelvir/ritonavir (Paxlovid®) is currently one of the few therapeutic options for coronavirus disease 2019 (COVID-19) curative treatment in non-oxygen-requiring adult patients at-high risk of progressing to severe disease. This recently approved boosted antiviral therapy presents a significant risk of drug-drug interactions (DDI).
Bihan, Kevin +8 more
openaire +4 more sources
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2 [PDF]
, 2022 Three directly acting antivirals (DAAs) demonstrated substantial reduction in COVID-19 hospitalizations and deaths in clinical trials. However, these agents did not completely prevent severe illness and are associated with cases of rebound illness and ...
Aittokallio, Tero +12 more
core +2 more sources
REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS
International Journal of Infectious Diseases, 2023 Intro: On May 24, 2022, the CDC issued a healthcare advisory after reports of COVID-19 symptoms returning (COVID-19 rebound) in certain patients two to eight days after treatment with Paxlovid (Ritonavir-Boosted Nirmatrevir). We describe two patients who
P. Periyasamy +3 more
doaj +1 more source
Familial Hypercholesterolemia Patients with COVID-19-Effective Cholesterol-Lowering Therapy is Urgent both during and after Infection [PDF]
, 2022 Heterozygous familial hypercholesterolemia (HeFH) patients are the prime example of subjects who are at high risk for both acute myocardial infarction (AMI) and ischemic stroke during, and post, SARS-CoV-2 infection.
Kovanen, Petri T. +2 more
core +1 more source
A case of the application of Paxlovid for a patient infected by the SARS-CoV-2 Omicron variant [PDF]
, 2023 Coronavirus disease 2019 (COVID-19) is a new acute respiratory infectious disease with high infectivity. To date, > 500 million cases of COVID-19 have been confirmed worldwide (World Health Organization).
Lu Zhang, Mei Wang, Xianwei Ye
core +1 more source
The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir. [PDF]
, 2023 The SARS-CoV-2 main protease (3CLpro) has an indispensable role in the viral life cycle and is a therapeutic target for the treatment of COVID-19. The potential of 3CLpro-inhibitors to select for drug-resistant variants needs to be established. Therefore,
Bardiot, Dorothée +24 more
core +2 more sources
Intrinsic and Relative Valuation of Pfizer Inc. [PDF]
, 2023 The aim of the thesis was to estimate the intrinsic and relative value of Pfizer Inc. by analysing both: Pfizer and the pharmaceutical industry. To create a multitude of valuation estimates the following valuation methods were utilized: Discounted Cash ...
Garshol, Eirik, Thornes, Johannes
core +3 more sources
Infectious Diseases and Therapy, 2023 Introduction Elderly patients are the most affected and vulnerable to COVID-19 and effective therapeutic interventions are urgently required. We clarified the safety and efficacy of Paxlovid in the treatment of elderly patients with coronavirus disease ...
Chengzhao Weng +8 more
doaj +1 more source
Antivirals for the treatment of mild and moderate COVID-19 in South Africa [PDF]
, 2023 While the majority of COVID‐19 cases in South Africa (SA) are mild, patients with severe COVID‐19 requiring hospitalisation present with significant morbidity and mortality and place a substantial burden on healthcare services.
Gengiah, T N +3 more
core +2 more sources